On Tuesday, BTIG updated their assessment of Glaukos Corporation (NYSE:GKOS), increasing the price target to $140 from $139 while maintaining a Buy rating. This adjustment follows Glaukos' third-quarter financial results for the fiscal year 2024, which surpassed both BTIG's and consensus estimates. The company reported a revenue of $96.7 million, marking a 23.9% year-over-year growth, adjusted for foreign exchange.
Glaukos' revenue from its glaucoma products reached $76.0 million, a 30% increase year-over-year, exceeding BTIG's estimate of $69.2 million. This surge was attributed to approximately $8.8 million in sales from iDose and a 12.3% growth in the U.S. sales of iStent infinite and the broader iStent portfolio. The company's international glaucoma business also showed strong performance, growing over 20%, while corneal health revenue was slightly below expectations at $20.6 million, a 5% year-over-year increase.
In response to the robust third-quarter performance, Glaukos raised its full-year revenue guidance to between $377 million and $379 million, representing an increase of 19.8% to 20.4%. This guidance accounts for approximately $5 million from the third-quarter outperformance.
Despite strong iDose sales, the company's fourth-quarter expectations remain conservative due to anticipated challenges, including the Medical Device Reporting Program (MDRP), changes in reimbursement for surgical glaucoma, and competition from Alcon (NYSE:ALC)'s Hydrus in key international markets.
BTIG remains optimistic about Glaukos' future, especially with the commercial infrastructure and reimbursement in place for iDose, predicting further growth in the fourth quarter of 2024 and into fiscal year 2025. The firm also anticipates that, as Glaukos overcomes headwinds in corneal health, its Epioxa product will begin to contribute to the company's performance.
In other recent news, Glaukos Corporation reported significant developments in its operations and financial performance. The company announced a 19% increase in second-quarter consolidated net sales, reaching $95.7 million, which led to an upward revision of its full-year 2024 net sales guidance to between $370 and $376 million. This growth was primarily attributed to its US interventional glaucoma franchises, including the iStent portfolio and iDose TR.
Glaukos also announced the redemption of its outstanding 2.75% Convertible Senior Notes due 2027, with a principal amount of $57.5 million. This financial maneuver is part of Glaukos' ongoing financial management strategy.
On the analyst front, Jefferies, Truist Securities, and Piper Sandler have all maintained positive ratings on Glaukos. Jefferies increased its price target on the company's shares to $155.00, up from the previous $145.00, highlighting the potential growth of Glaukos' iDose product. Truist Securities maintained a Buy rating and a price target of $152.00, while Piper Sandler maintained an Overweight rating and a $140.00 price target.
Lastly, Glaukos reported successful results from its second Phase 3 trial for Epioxa, a non-invasive drug therapy designed for keratoconus treatment. The trial met its primary efficacy endpoint, demonstrating a significant improvement in corneal curvature.
InvestingPro Insights
Glaukos Corporation's recent performance and BTIG's optimistic outlook are reflected in several key metrics from InvestingPro. The company's revenue growth of 15.14% over the last twelve months, with a notable 19.02% quarterly growth in Q2 2024, aligns with the strong third-quarter results mentioned in the article. This growth trajectory supports BTIG's decision to raise the price target.
InvestingPro Tips highlight that Glaukos has shown a "High return over the last year" and is "Trading near 52-week high," which corroborates the positive sentiment expressed in BTIG's analysis. The stock's impressive 104.61% price total return over the past year further underscores its strong market performance.
However, investors should note that Glaukos "Operates with a moderate level of debt" and is "Not profitable over the last twelve months," with a negative operating income margin of -34.95%. This suggests that while the company is experiencing significant growth, it is still focusing on expansion rather than immediate profitability, which is common in the medical device sector.
For readers interested in a more comprehensive analysis, InvestingPro offers 12 additional tips for Glaukos, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.